Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S101 CAR-T in CD7-positive R/R T-LBL/ALL
NCT07244380Phase 2Not yet recruiting
- Sponsor
- Senlang Bio
- Start
- Nov 2025
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
A Phase 2 trial of SENL101 in T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoblastic lymphoma (T-LBL), sponsored by Senlang Bio. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
SENL101
03
Conditions
T-cell acute lymphoblastic leukemia (T-ALL)T-cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT07244380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07244380.